<?xml version='1.0' encoding='utf-8'?>
<document id="18004569"><sentence text="Imatinib inhibition of fludarabine uptake in T-lymphocytes."><entity charOffset="0-8" id="DDI-PubMed.18004569.s1.e0" text="Imatinib" /><entity charOffset="23-34" id="DDI-PubMed.18004569.s1.e1" text="fludarabine" /><pair ddi="false" e1="DDI-PubMed.18004569.s1.e0" e2="DDI-PubMed.18004569.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18004569.s1.e0" e2="DDI-PubMed.18004569.s1.e1" /></sentence><sentence text="We investigated the potential drug-drug interaction between imatinib and fludarabine, which may be concomitantly administered in chronic myeloid leukemia (CML) patients receiving fludarabine-based conditioning for allogeneic hematopoietic cell transplantation (HCT)"><entity charOffset="60-68" id="DDI-PubMed.18004569.s2.e0" text="imatinib" /><entity charOffset="73-84" id="DDI-PubMed.18004569.s2.e1" text="fludarabine" /><entity charOffset="179-190" id="DDI-PubMed.18004569.s2.e2" text="fludarabine" /><pair ddi="false" e1="DDI-PubMed.18004569.s2.e0" e2="DDI-PubMed.18004569.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18004569.s2.e0" e2="DDI-PubMed.18004569.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18004569.s2.e0" e2="DDI-PubMed.18004569.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18004569.s2.e1" e2="DDI-PubMed.18004569.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18004569.s2.e1" e2="DDI-PubMed.18004569.s2.e2" /></sentence><sentence text=" Imatinib is an inhibitor of human equilibrative transporters (hENTs), which are responsible for the intracellular uptake of fludarabine"><entity charOffset="1-9" id="DDI-PubMed.18004569.s3.e0" text="Imatinib" /><entity charOffset="125-136" id="DDI-PubMed.18004569.s3.e1" text="fludarabine" /><pair ddi="false" e1="DDI-PubMed.18004569.s3.e0" e2="DDI-PubMed.18004569.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18004569.s3.e0" e2="DDI-PubMed.18004569.s3.e1" /></sentence><sentence text="" /><sentence text="Intracellular accumulation of fludarabine triphosphate (F-ara-ATP), the active metabolite of fludarabine, was measured in CD4(+) and CD8(+) T-lymphocytes isolated from healthy volunteers, which were treated in vitro with fludarabine alone, and in the presence of either imatinib or NBMPR, a known hENT inhibitor"><entity charOffset="30-54" id="DDI-PubMed.18004569.s5.e0" text="fludarabine triphosphate" /><entity charOffset="56-65" id="DDI-PubMed.18004569.s5.e1" text="F-ara-ATP" /><entity charOffset="93-104" id="DDI-PubMed.18004569.s5.e2" text="fludarabine" /><entity charOffset="221-232" id="DDI-PubMed.18004569.s5.e3" text="fludarabine" /><entity charOffset="270-278" id="DDI-PubMed.18004569.s5.e4" text="imatinib" /><entity charOffset="282-287" id="DDI-PubMed.18004569.s5.e5" text="NBMPR" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e0" e2="DDI-PubMed.18004569.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e0" e2="DDI-PubMed.18004569.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e0" e2="DDI-PubMed.18004569.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e0" e2="DDI-PubMed.18004569.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e0" e2="DDI-PubMed.18004569.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e0" e2="DDI-PubMed.18004569.s5.e5" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e1" e2="DDI-PubMed.18004569.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e1" e2="DDI-PubMed.18004569.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e1" e2="DDI-PubMed.18004569.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e1" e2="DDI-PubMed.18004569.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e1" e2="DDI-PubMed.18004569.s5.e5" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e2" e2="DDI-PubMed.18004569.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e2" e2="DDI-PubMed.18004569.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e2" e2="DDI-PubMed.18004569.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e2" e2="DDI-PubMed.18004569.s5.e5" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e3" e2="DDI-PubMed.18004569.s5.e3" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e3" e2="DDI-PubMed.18004569.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e3" e2="DDI-PubMed.18004569.s5.e5" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e4" e2="DDI-PubMed.18004569.s5.e4" /><pair ddi="false" e1="DDI-PubMed.18004569.s5.e4" e2="DDI-PubMed.18004569.s5.e5" /></sentence><sentence text="" /><sentence text="Imatinib significantly inhibited F-ara-ATP accumulation in CD4(+) and CD8(+) T-lymphocytes in a concentration-dependent manner"><entity charOffset="0-8" id="DDI-PubMed.18004569.s7.e0" text="Imatinib" /></sentence><sentence text=" The observed imatinib inhibition was comparable to inhibition observed with NBMPR"><entity charOffset="14-22" id="DDI-PubMed.18004569.s8.e0" text="imatinib" /><entity charOffset="77-84" id="DDI-PubMed.18004569.s8.e1" text="NBMPR" /><pair ddi="false" e1="DDI-PubMed.18004569.s8.e0" e2="DDI-PubMed.18004569.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18004569.s8.e0" e2="DDI-PubMed.18004569.s8.e1" /></sentence><sentence text=" The inhibition of F-ara-ATP by imatinib is likely due to inhibition of nucleoside transporters hENT1 and hENT2"><entity charOffset="32-40" id="DDI-PubMed.18004569.s9.e0" text="imatinib" /></sentence><sentence text="" /><sentence text="There is significant in vitro drug interaction between imatinib and fludarabine"><entity charOffset="55-63" id="DDI-PubMed.18004569.s11.e0" text="imatinib" /><entity charOffset="68-79" id="DDI-PubMed.18004569.s11.e1" text="fludarabine" /><pair ddi="false" e1="DDI-PubMed.18004569.s11.e0" e2="DDI-PubMed.18004569.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18004569.s11.e0" e2="DDI-PubMed.18004569.s11.e1" /></sentence><sentence text=" This effect may be of important consideration in patients receiving fludarabine-based conditioning prior to HCT"><entity charOffset="69-80" id="DDI-PubMed.18004569.s12.e0" text="fludarabine" /></sentence><sentence text="" /></document>